Case Report: Twenty years of metreleptin therapy in congenital generalized lipodystrophy type 1: the longest reported follow-up to date

Congenital generalized lipodystrophy (CGL) is a rare disorder marked by near-total loss of adipose tissue and severe metabolic disturbances due to leptin deficiency and the inability to store nutrients in adipose tissue effectively. Metreleptin is the only approved leptin replacement therapy for thi...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Elise Van der Borght, Bart Van der Schueren, Roman Vangoitsenhoven, David Cassiman, Baris Akinci, Rebecca J. Brown, Elif A. Oral, Ann Mertens, Pieter-Jan Martens
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Frontiers Media S.A. 2026-05-01
Serie:	Frontiers in Endocrinology
Soggetti:	compliance AGPAT2 congenital generalized lipodystrophy type 1 metreleptin therapy pregnancy
Accesso online:	https://www.frontiersin.org/articles/10.3389/fendo.2026.1815903/full
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!